These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27250673)

  • 1. Concise Review: Application of In Vitro Transcribed Messenger RNA for Cellular Engineering and Reprogramming: Progress and Challenges.
    Steinle H; Behring A; Schlensak C; Wendel HP; Avci-Adali M
    Stem Cells; 2017 Jan; 35(1):68-79. PubMed ID: 27250673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine.
    Kwon H; Kim M; Seo Y; Moon YS; Lee HJ; Lee K; Lee H
    Biomaterials; 2018 Feb; 156():172-193. PubMed ID: 29197748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust Differentiation of mRNA-Reprogrammed Human Induced Pluripotent Stem Cells Toward a Retinal Lineage.
    Sridhar A; Ohlemacher SK; Langer KB; Meyer JS
    Stem Cells Transl Med; 2016 Apr; 5(4):417-26. PubMed ID: 26933039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA.
    Michel T; Link A; Abraham MK; Schlensak C; Peter K; Wendel HP; Wang X; Krajewski S
    J Vis Exp; 2019 Feb; (144):. PubMed ID: 30774119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IVT-mRNA reprogramming of myeloid cells for cancer immunotherapy.
    Jolly KJ; Zhang F
    Adv Pharmacol; 2024; 100():247-288. PubMed ID: 39034054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems.
    Guan S; Rosenecker J
    Gene Ther; 2017 Mar; 24(3):133-143. PubMed ID: 28094775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nebulisation of IVT mRNA Complexes for Intrapulmonary Administration.
    Johler SM; Rejman J; Guan S; Rosenecker J
    PLoS One; 2015; 10(9):e0137504. PubMed ID: 26352268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic mRNA Reprogramming of Human Fibroblast Cells.
    Liu J; Verma PJ
    Methods Mol Biol; 2015; 1330():17-28. PubMed ID: 26621585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploitation of Synthetic mRNA To Drive Immune Effector Cell Recruitment and Functional Reprogramming In Vivo.
    Xu Y; Huang L; Kirschman JL; Vanover DA; Tiwari PM; Santangelo PJ; Shen X; Russell DG
    J Immunol; 2019 Jan; 202(2):608-617. PubMed ID: 30541883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies.
    Nielsen JS; Wick DA; Tran E; Nelson BH; Webb JR
    J Immunol Methods; 2010 Aug; 360(1-2):149-56. PubMed ID: 20637775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Messenger RNA Delivery for Tissue Engineering and Regenerative Medicine Applications.
    Patel S; Athirasala A; Menezes PP; Ashwanikumar N; Zou T; Sahay G; Bertassoni LE
    Tissue Eng Part A; 2019 Jan; 25(1-2):91-112. PubMed ID: 29661055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration-free reprogramming of human somatic cells to induced pluripotent stem cells (iPSCs) without viral vectors, recombinant DNA, and genetic modification.
    Heng BC; Fussenegger M
    Methods Mol Biol; 2014; 1151():75-94. PubMed ID: 24838880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reprogramming to pluripotency and differentiation of cells with synthetic mRNA.
    Wang P; Na J
    Methods Mol Biol; 2013; 969():221-33. PubMed ID: 23296937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pluripotent state induction in mouse embryonic fibroblast using mRNAs of reprogramming factors.
    El-Sayed AK; Zhang Z; Zhang L; Liu Z; Abbott LC; Zhang Y; Li B
    Int J Mol Sci; 2014 Nov; 15(12):21840-64. PubMed ID: 25437916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mRNA-based therapeutics--developing a new class of drugs.
    Sahin U; Karikó K; Türeci Ö
    Nat Rev Drug Discov; 2014 Oct; 13(10):759-80. PubMed ID: 25233993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mRNA-based therapies: Preclinical and clinical applications.
    Qureischi M; Mohr J; Arellano-Viera E; Knudsen SE; Vohidov F; Garitano-Trojaola A
    Int Rev Cell Mol Biol; 2022; 372():1-54. PubMed ID: 36064262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell engineering with synthetic messenger RNA.
    Rabinovich PM; Weissman SM
    Methods Mol Biol; 2013; 969():3-28. PubMed ID: 23296924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Assembly, Production, and Transfection of Synthetic Modified mRNA.
    Oh S; Kessler JA
    Methods; 2018 Jan; 133():29-43. PubMed ID: 29080741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of human β-thalassemia induced pluripotent cell lines by reprogramming of bone marrow-derived mesenchymal stromal cells using modified mRNA.
    Varela I; Karagiannidou A; Oikonomakis V; Tzetis M; Tzanoudaki M; Siapati EK; Vassilopoulos G; Graphakos S; Kanavakis E; Goussetis E
    Cell Reprogram; 2014 Dec; 16(6):447-55. PubMed ID: 25354259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes.
    Grünebach F; Kayser K; Weck MM; Müller MR; Appel S; Brossart P
    Cancer Gene Ther; 2005 Sep; 12(9):749-56. PubMed ID: 15877082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.